

आई.सी.एम.आर.-राष्ट्रीय मलेरिया अनुसंधान संस्थान स्वास्थ्य अनुसंधान विभाग, स्वास्थ्य एवं परिवार कल्याण मंत्रालय, भारत सरकार ICMR-National Institute of Malaria Research Department of Health Research Ministry of Health and Family Welfare, Government of India

No.2/65/2020-21/Store February,7th, 2022

Invitation for Expression of Interest for providing Clinical Trials Liability Insurance

ICMR-National Institute of Malaria Research intends to conduct a clinical trial, titled "Evaluation of Safety and Efficacy of Curcumin (Biocurcumax capsule) as an Adjunct Drug to Standard Therapy [(Artesunate)+(Sulfadoxine - Pyrimethamine) tablet] for Treatment of Uncomplicated P. falciparum Malaria" for treatment of uncomplicated P. falciparum Malaria with 130 patients meeting the inclusion and exclusion criteria across 2 sites (Odisha & Chhattisgarh) over a period of 2 years.

This is a Phase IIa Randomized, Double Blind, Comparative, two site study funded by Department of Biotechnology, with the primary objective to assess the Day 28 PCR (Polymerase chain reaction) corrected Adequate Clinical and Parasitological Response (ACPR) of Curcumin (Biocurcumax capsule) as add on therapy to Artesunate + Sulfadoxine - Pyrimethamine in patients with uncomplicated P. falciparum malaria.

Request for proposals are invited from eligible parties who are interested in providing clinical trials liability policy or liability insurance, indicating the conditions and extent of coverage, date of commencement and expiry of coverage, and conditions thereof, including the premium and other costs, as per rules, for the aforementioned studies.

The terms for the policy are —

- 1. Medical Management of Serious Adverse Event's (SAEs) including COVID-19 and compensation as per the applicable guidelines under Drugs and Cosmetics Act and Ethics Committee decision.
- 2. Aggregate insurance of 2 Crore Rupees per year

Additional Insured - All the staff involved in the conduct of the study at NIMR and both the study sites (Odisha &Chhattisgarh).

Invitation of quotations

The quotations with a validity of 60 days may be submittedsealed pack envelop within 21 days from the date of publication upto (08/03/2022 up to 3.00 pm) for the Trial Insurance to safeguard all the trial participants and the staff involved, for a period of 01/04/2022 to31.03.2023. The Expression of Interest may be sent to The Director, National Institute of Malaria Research Room No. 405 (Store section), Sector-8, Dwarka, New Delhi-110 077. Further the quotations will not be accepted or entertained through mail.

Kindly mention this No. 2/65/2020-21/store (Clinical Trial insurance) with due date on sealed pack envelope. Any clarification may be sought upto 1 week on email: purchase.nimr@gmail.com with cc to: tomarrst@gmail.com

हमारे संस्थान मे आपके हिन्दी पत्रों का स्वागत है।

सैक्टर -8 द्वारका नई दिल्ली —110077,भारत Dwarka, Sector - 8 New Delhi — 110077, India



आई.सी.एम.आर.-राष्ट्रीय मलेरिया अनुसंधान संस्थान स्वास्थ्य अनुसंधान विभाग, स्वास्थ्य एवं परिवार कल्याण मंत्रालय, भारत सरकार ICMR-National Institute of Malaria Research Department of Health Research Ministry of Health and Family Welfare, Government of India

हमारे संस्थान मे आपके हिन्दी पत्रों का स्वागत है।



आई.सी.एम.आर.-राष्ट्रीय मलेरिया अनुसंधान संस्थान स्वास्थ्य अनुसंधान विभाग, स्वास्थ्य एवं परिवार कल्याण मंत्रालय, भारत सरकार ICMR-National Institute of Malaria Research Department of Health Research Ministry of Health and Family Welfare, Government of India

of the study at NIMR and both the study sites (Odisha & Chhattisgarh).

हमारे संस्थान मे आपके हिन्दी पत्रों का स्वागत है।